Nifedipine (Procardia®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2022/Apr. Preeclampsia and High Blood Pressure during Pregnancy. https://www.acog.org/womens-health/faqs/preeclampsia-and-high-blood-pressure-during-pregnancy
- Anderson PO, et al 2020. Drug treatment of Raynaud's phenomenon of the nipple. Breastfeed Med 15:686-8.
- Benoff S, et al. 1994. The effect of calcium ion channel blockers on sperm fertilization potential. Fertil Steril 62:606-17.
- Bortolus R, et al. 2000. Nifedipine administered in pregnancy: Effect on the development of children at 18 months. BJOG 107:792-794.
- Davis RL, et al 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmocoepidemiol Drug Saf 20:13-145.
- Dublin S, et al. 2022. Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: a retrospective cohort study. PLoS One 17(5):e0268284
- George R, et. 2022. Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 40(10):1876-1886.
- Houtzager BA, et al. 2006. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG. 2006 Mar; 113(3):324-31.
- Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. Am J Obstet Gynecol 174:823-828.
- Malfará BN, et al. 2019. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. Reprod Toxicol 85:1-5.
- Penny WJ, Lewis MJ. 1989. Nifedipine is excreted in human milk. Eur J Clin Pharmacol. 36(4):427-8.
- Tabacova SA, et al. 2002. Developmental abnormalities reported to FDA in association with nifedipine treatment in pregnancy. Teratology; 65:368.
- Taddio A, et al 1996. Is nifedipine use during labor and breast-feeding safe for the neonate? Clin Investig Med 19:S11. Abstract.
- Weber-Schoendorfer C, et al. 2008. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 26(1): 24-30.
- Wu M, et al 2012. Raynaud's phenomenon of the nipple. Obstet Gynecol. 119(2 Pt 2):447-9.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de agosto de 2024.

Nifedipine (Procardia®)

- Agrawal M, et al. 2022. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clinical endocrinology, 96(6):857–868.
- Akmal A, Kung J. 2014. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf, 13(10):1397-1406.
- Alexander EK, et al. 2017. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid: official journal of the American Thyroid Association, 27(3):315–389.
- American College of Obstetricians and Gynecology. 2020. Thyroid disease in pregnancy. ACOG Practice Bulletin, Number 223. Obstet Gynecol, 135(6):e261-e274.
- Andersen SL, et al. 2013. Birth Defects after early pregnancy use of antithyroid drugs: A Danish nationwide study. J Clin Endocrinol Metab, 98(11):4374-4381.
- Andersen SL, et al. 2017. Birth Defects after early pregnancy use of antithyroid drugs: A Swedish nationwide study. Euro J Endocrinol, 177(4):369-378.
- Andersen SL, Andersen S. 2020. Antithyroid drugs and birth defects. Thyroid Res, 13:11.
- Arata N, et al. 2012. Pregnancy outcomes of exposure to methimazole (POEM) study: an interim report. Japanese journal of clinical medicine, 70(11):1976-1982.
- Awosika AO, et al. 2023. Methimazole. StatPearls [Internet], Treasure Island (FL), available from: https://www.ncbi.nlm.nih.gov/books/NBK545223/
- Azizi F. 2003. Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. J Endocrinol Invest, 26:301-304.
- Baid SK, Merke DP. 2007. Aplasia cutis congenita following in utero methimazole exposure. J Pediatr Endocrinol Metab, 20:585-586.
- Barbero P, et al. 2008. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet, 146A(18):2390-2395.
- Cassina M, et al. 2012. Pharmacologic treatment of hyperthyroidism during pregnancy. Birth Defects Res A Clin Mol Teratol, 94(8):612-619.
- Chan GW, Mandel SJ. 2007. Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab; 3(6):470-8.
- Chen CH, et al. 2011. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. BJOG, 118:1365-1373.
- Clementi M, et al. 1999. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet, 83:43-46.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. Pediatrics, 108:776-789.
- Cooper DS. 1987. Antithyroid drugs: to breast-feed or not to breast-feed. Am J Obstet Gynecol, 157:234-235.

- Diav-Citrin O, Ornoy A. 2002. Teratogen update: antithyroid drugs-methimazole, carbimazole, and propylthiouracil. Teratology, 65:38-44.
- Di Gianantonio E, et al. 2001. Adverse effects of prenatal methimazole exposure. Teratology, 64(5):262–266.
- Dumi M, et al. 2002. Choanal stenosis, hypothelia, deafness, recurrent dacryocystitis, neck fistulas, short stature, and microcephaly: report of a case. Am J Med Genet, 113:295-297.
- Dumitrascu MC, et al. 2021. Hyperthyroidism management during pregnancy and lactation (Review). Exp Ther Med, 22(3):960.
- Eisenstein Z, et al. 1992. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J Pediatr, 151:558-559.
- Ferraris S, et al. 2003. Malformations following methimazole exposure in utero: an open issue. Birth Defects Res (Part A), 67:989-992.
- Francis T, et al. 2020. Safety of antithyroid drugs in pregnancy: update and therapy implications. Expert Opin Drug Saf, 19(5):565-576.
- Gianetti E, et al. 2015. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest, 38(9):977-985.
- Greenberg F. 1987. Brief clinical report: Choanal atresia and athelia: Methimazole teratogenicity or a new syndrome? Am J Med Genet, 28:931-934.
- Gripp KW, et al. 2011. Grade 1 microtia, wide anterior fontanel and novel type trachea-esophageal fistula in methimazole embryopathy. Am J Med Genet A, 155A(3):526-533.
- Howley MM, et al. 2017. Thyroid medication use and birth defects in the National Birth Defects Prevention Study. Birth Defects Res, 109(18):1471-1481.
- Hudzik B, Zubelewicz-Szkodzinska B. 2016. Antithyroid drugs during breastfeeding. Clin Endocrinol (Oxf), 85(6):827-830.
- Johnsson E, et al. 1997. Severe malformations in infant born to hyperthyroid woman on methimazole. Lancet, 350:1520.
- Karlsson FA, et al. 2002. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab, 87(2):947-949.
- Korelitz JJ, et al. 2013. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid, 23:758-765.
- Martin-Denavit T, et al. 2000. Ectodermal abnormalities associated with methimazole intrauterine exposure [letter]. Am J Med Genet, 94:338-340.
- Methimazole tablets, USP Prescribing Information. Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977. Accessed May 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040350s016lbl.pdf
- Mitsuda N, et al. 1992. Risk factors for developmental disorders in infants born to women with Graves disease. Obstet Gynecol; 80(3 Pt 1):359-64.
- Momotani M, et al. 1984. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxford), 20:695-700.
- Purnamasari D, et al. 2019. Gastroschisis Following Treatment with High-Dose Methimazole in Pregnancy: A Case Report. Drug Saf Case Rep, 6(1):5.
- Radetti G, et al. 2002. Foetal and neonatal thyroid disorders. Minerva Pediatr; 54(5):383-400.
- Rasmussen SA, et al. 2007. Maternal thyroid disease as a risk factor for craniosynostosis. Obstetrics and gynecology, 110(2 Pt 1):369–377.
- Romeo AF, Obican SG. 2020. Teratogen Update: Antithyroid Medications. Birth Defects Res, 112(15):1150-1170.
- Sargent KA, et al. 1994. Apparent scalp-ear-nipple (Findlay) syndrome in a neonate exposed to methimazole in-utero. Am J Hum Genet, 55:A312.
- Sato Y, et al. 2014. A case of fetal hyperthyroidism treated with maternal administration of methimazole. J Perinatol, 34(12):945-347.
- Seo GH, et al. 2018. Antithyroid drugs and congenital malformations. A nationwide Korean cohort study. Ann Intern Med, 168(6):405-413.

- Seoud M, et al. 2003. Gastrointestinal malformations in two infants born to women with hyperthyroidism untreated in the first trimester. Am J Perinatol, 20:59-62.
- Shepard TH, et al. 2002. Update on new developments in the study of human teratogens. Teratology, 65(4):153–161.
- Stagnaro-Green A, et al. 2011. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid, 21:1081-1125.
- Tegler L, Lindstrom B. 1980. Antithyroid drugs in milk. Lancet, 2:591.
- The WHO Working Group, Bennet PN (ed). 1988. Drugs and Human Lactation. Elsevier, Amsterdam, New York, Oxford, pp. 196-197.
- Tonacchera M, et al. 2020. Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. J Endocrinol Invest, 43(2):257-265.
- Wilson LC, et al. 1998. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet, 75:220-222.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de agosto de 2024.

Nifedipine (Procardia®)

Selected References:

- Camera G and Pregliasco P. 1992. Ear malformation in baby born to mother using isotretinoin cream. Lancet, 339:687.
- De Wals P. et al. 1991. Association between holoprosencephaly and exposure to topical retinoids: results of the EUROCAT survey. Paediatr Perinat Epidemiol, 5:445-447.
- Jick S, et al. 1993. First trimester topical tretinoin and congenital disorders. Lancet, 341:1181-1182.
- Kaplan YC, et al. 2015. Pregnancy outcomes following first-trimester exposure to topical retinoids: A systematic review and meta-analysis. Br J Dematol, 173:1132-1141.

- Loureiro KD, et al. 2005. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. American Journal of Medical Genetics, 136A:117-121.
- Lipson AH, et al. 1993. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet, 341:1352-1353.
- MacDonald SC, et al. 2019. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. Pharmacoepidemiol Drug Saf 28(9):1211-1221.
- Panchaud A, et al. 2012. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol, 52:1844-1851.
- Ross SA, et al. 2000. Retinoids in embryonal development. Physiol Rev, 80(3):1021-1054.
- Selcen D, et al. 2000. Otocerebral anomalies associated with topical tretinoin use. Brain Dev 22:218-220.
- Shapiro L, et al. 1997. Safety of first trimester exposure to topical tretinoin: prospective cohort study. Lancet, 350:1143-1144.
- Veraldi S, et al. 2016. Are topical retinoids teratogenic? G Ital Dermatol Venereol. 151(6):700-705.
- Williams AL et al. 2020. Teratogen update: Topical use and third-generation retinoids. Birth Defects Res, 112(15):1105-1114.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de agosto de 2024.

Nifedipine (Procardia®)

Selected References:

- Alhomoud MA, et al. The Potential Preventive Effect of Pregnancy and Breastfeeding on Multiple Sclerosis. Eur Neurol. 2021;84(2):71-84.
- Amato MP and Portaccio E. 2015. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 29(3): 207-20.

- Andersen JB, et al. Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis: A Nationwide Danish Cross-sectional Study. Neurol Clin Pract. 2021 Aug;11(4):280-290.
- Arafa A, et al. Does multiple sclerosis increase the risk of preeclampsia? A systematic review and meta-analysis. Hypertens Pregnancy. 2021 Aug;40(3):180-185.
- Ashtari F, et al. Investigating the interaction between fertility, pregnancy, and multiple sclerosis. J Educ Health Promot. 2021 Jun 30;10:220.
- Berenguer-Ruiz L, et al. 2019. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. J Neurol 266(10):2512-2517.
- Bove R. 2016. Women's Issues in Multiple Sclerosis. Semin Neurol. 36(2):154-62.
- Bsteh G, et al. 2020. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Australia. Mult Scler. 26(1): 69-78.
- Carta A, et al. Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. Mult Scler J Exp Transl Clin. 2021 May 28;7(2).
- Coyle PK. 2016. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. May;9(3):198-210.
- Cuello JP, et al. 2017. Multiple sclerosis and pregnancy: a single-centre prospective comparative study. Neurologia. 32(2):92-98.
- D'Amico E, et al. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Mult Scler. 2021 Dec;27(14):2284-2287.
- Eid K, et al. Perinatal Depression and Anxiety in Women With Multiple Sclerosis: A Population-Based Cohort Study. Neurology. 2021 Jun 8;96(23):e2789-e2800.
- Fragoso YD, et al. 2013. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis, Clin Neurol Neurosurg. Feb;115(2): 154-9.
- Houtchens MK, et al. 2018. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018;91:e1559–69.
- Hughes SE, et al. 2014. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 20(6) 739–746.
- Jokubaitis VG, et al; MS Base Study Group. 2016. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 80(1):89-100.
- Lamaita R, et al. Multiple Sclerosis in Pregnancy and its Role in Female Fertility: A Systematic Review. JBRA Assist Reprod. 2021 Jul 21;25(3):493-499.
- Langer-Gould A. 2019. Pregnancy and family planning in multiple sclerosis. Continuum 25(3):773-792.
- Lu E, et al. 2014. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler Feb;20(9):1260-1264.
- Mahlanza TD, et al. Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis. Mult Scler. 2021 Jan;27(1):79-89.
- Massarotti C, et al. Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. J Clin Med. 2021 Nov 19;10(22):5401.
- Moccia M, et al. 2023. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. Journal of Neurology, Neurosurgery & Psychiatry, 94:689-697.
- Neuteboom RF, et al. 2012. Pregnancy in multiple sclerosis: clinical and self-report scales. J Neurol. 259(2):311-7.
- Paidas PJ, et al. 2012. Pregnancy and multiple sclerosis (MS): A beneficial association. Possible therapeutic application of embryo-specific Pre-implantation Factor (PIF*). Am J Reprod Immunol 68(6):456-64.
- Pecori C, et al. 2014. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol. 14:114.
- Sadovnick D. et al. 2023. The Canadian Multiple Sclerosis Pregnancy Study: First-trimester miscarriages in women with multiple sclerosis. Multiple Sclerosis Journal, 29(3), 407-414.
- Safarinejad MR. 2008. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in

multiple sclerosis. J Neuroendocrinol. 20(12):1368-1375.

- Villaverde-Gonzalez R, et al. 2020. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study. Mult Scler Relat Disord. 46:102518.
- Voskuhl R, Momtazee C. 2017. Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding. Neurotherapeutics. 14(4):974-984.
- Weber-Schoendorfer C and Schaefer C. 2009. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 15(9):1037-1042.
- Zanghi A, et al. 2020. Pregnancy and the postpartum period in women with relatpsing-remitting multiple sclerosis treated with old and new disease-modifying treatments: A real-world multicenter experience. Front Neurol 11:105.
- Ziemssen T, et al. 2001. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 24(13):979-990.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de agosto de 2024.

Nifedipine (Procardia®)

Selected References:

- Abdel-Aleem H, et al. 2003. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol; 108(1):25-8.
- Abdelshafy A, et al. 2019. Sublingual vs vaginal misoprostol for completion of first trimester missed abortion: a randomised controlled trial. Eur J Contracept Reprod Health Care 12: 1-6.
- Ameri A, et al. 2024. Effect of misoprostol versus oxytocin on delivery outcomes after labour induction in pregnant women: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 292:75-88.
- Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol; 207:188-192.

- Bernard N, et al. 2013. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG; 120:568-575.
- Bord I, et al. 2014. Misoprostol treatment for early pregnancy failure does not impair future fertility. Gynecol Endocrinol; 30(4):316-9.
- Brasil R, et al. 2000. Misoprostol and congenital anomalies. Pharmacoepidemiol Drug Saf; 9(5):401-3.
- Brown SE, et al. 2001. Vaginal misoprostol enhances intrauterine insemination. Hum Reprod 2001; 16(1):96-101.
- Coelho KE, et al. 2000. Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet; 95(4):297-301.
- da Silva Dal Pizzol T, et al. 2006. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol; 22(4):666-71.
- Dal Pizzol Tda S, et al. 2008. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad Saude Publica; 24(6):1447-53.
- Genest DR, et al. 1999. Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Clin Dysmorphol; 8(1):53-8.
- Gonzalez CH, et al. 1993. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet; 47(1):59-64.
- Gonzalez CH, et al. 1998. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet; 351(9116):1624-7.
- Holmes LB, et al. 2018. Malformations attributed to the process of vascular disruption. Birth Defects Res; 110(2):98-107.
- Kandahari N, et al. 2023. Fetal heart rate patterns and the incidence of adverse events after oral misoprostol administration for cervical ripening among low-risk pregnancies. J Matern Fetal Neonatal Med. 36(1):2199344.
- Kim C, et al. 2017. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev; 1(1):CD007223.
- Orioli IM, Castilla EE. 2000. Epidemiological assessment of misoprostol teratogenicity. BJOG; 107(4):519-23.
- Ozbasli E, et al. 2022. Labor induction with intravaginal misoprostol versus spontaneous labor: maternal and neonatal outcomes. Biomed Res Int. 2022:2826927.
- Pastuszak AL, et al. 1998. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med; 338(26):1881-5.
- Patel F, Cusack J. 2019. Möbius sequence with central hypoventilation in a neonate after failed elective medical termination of pregnancy. Arch Dis Child Fetal Neonatal Ed; 104(1):F49.
- Pfizer Laboratories Div Pfizer Inc. Last updated July 9, 2021. Cytotec drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12.
- Schuler L, et al. 1999. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective controlled study. Reprod Toxicol; 13:147-151.
- Shimizu T, et al. 1992. Prostaglandin E1, E2, and F2 alpha in human milk and plasma. Biol Neonate; 61:222–5.
- Song J. 2000. Use of misoprostol in obstetrics and gynecology. Obstet Gynecol Surv; 55(8):503-10.
- van Look PF, von Hertzen H. 1995. Misoprostol and birth defects. BMJ; 310(6972):128.
- Vargas FR, et al. 2000. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet; 95(4):302-6.
- Vauzelle C, et al. 2013. Birth defects after exposure to misoprostol in the first trimester of pregnancy: Prospective follow-up study. Reprod Toxicol; 36:98-103.
- Vendramini-Pittoli S, et al. 2013. Clinical findings in children with congenital anomalies and misoprostol intrauterine exposure: a study of 38 cases. J Pediatr Genet. 2013 Dec;2(4):173-80.
- Vogel D, et al. 2004. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol; 191:2168-73.

- Yip SK, et al. 2000. Misoprostol’s effect on uterine arterial blood flow and fetal heart rate in early pregnancy. Obstet Gynecol; 95(2):232-5.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de agosto de 2024.